Skip to content

Dose-effect relationship of rimaazulene mesylate used in adult gastroscopy

Dose-effect relationship of rimaazulene mesylate used in adult gastroscopy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057446
Enrollment
Unknown
Registered
2022-03-12
Start date
2022-03-15
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painless gastroscopy

Interventions

one:Injection of remimazolam

Sponsors

Zhuji People ' s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age = 18 years; 2. ASA Class I - II; 3. Volunteer to join the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women and those who have a birth plan within three months; 2. Patients with mental illness; 3. Heart, lung, brain, liver, kidney and vascular diseases; 4. Have a long history of taking psychoactive or sedative hypnotic drugs; 5. Patients allergic to the test drug; 6. Patients treated under microscope; 7. Acute upper gastrointestinal bleeding.

Design outcomes

Primary

MeasureTime frame
Induction dose of rimaazolam;

Secondary

MeasureTime frame
systolic pressure;diastolic pressure;mean arterial pressure;respiratory rate;heart rate;oxygen saturation;induced reaction;Patients ’ sleeping time;examination time;Drug addition name;administration timing of drug;Arousal time after gastroscopy;

Countries

China

Contacts

Public ContactYan Chen

Zhuji People’ s Hospital

1844786725@qq.com+86 13606853009

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026